慢阻肺药物治疗:乐观的理由
本文综述慢阻肺现有药物治疗的循证证据并给出实践建议。可吸入药物仍是首选途径,大环内酯类、罗氟司特等全身药物及部分生物制剂带来新方向。最迫切的需求是研究早期干预,因既往研究多在60岁以上、病程已充分进展的患者中进行。
要点
- 吸入药物是慢阻肺多维管理的核心,单、双、三联制剂选择众多。
- 大环内酯类、罗氟司特及部分生物制剂初步结果支持新药或改剂型开发。
- 既往研究多在60岁以上患者中开展,亟需研究疾病早期用药效果。
核心结论
- 慢阻肺可用药物数量增加,主要来自对旧化合物的改良,疗效明确,应作为多维管理的核心。
- 吸入途径仍是首选,但全身药物和生物制剂的初步结果提示新药开发方向。
- 最迫切的需求是研究这些药物在疾病早期阶段的效果。
研究设计与样本
- 综述,基于当前证据回顾慢阻肺可用药物治疗并给出实践建议。
- 原文未报告检索范围、纳入研究数量或样本量。
主要发现
- 过去数十年慢阻肺药物增多,多为旧化合物改良后效力更强、作用时间更长、装置更优。
- 药物已可及单药、双药甚至三药联合,虽试图简化给药,但也导致制剂种类繁多。
- 吸入药物疗效明确,应作为慢阻肺患者多维管理的中心组成部分。
- 大环内酯类和罗氟司特等全身药物取得有利结果,部分生物制剂有初步结果。
- 多数甚至全部研究在通常超过60岁的患者中进行,此时疾病自然病程多已充分进展。
临床怎么用
- 将吸入药物作为慢阻肺多维管理的核心组成部分。
- 吸入途径仍为首选给药途径。
- 关注大环内酯类、罗氟司特及生物制剂等全身用药的进展。
- 重视在疾病早期阶段评估药物效果的研究需求。
局限性
- 原文未报告检索范围、纳入研究数量或样本量。
- 多数甚至全部研究在通常超过60岁的患者中进行,疾病早期用药证据不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The number of pharmacological medications available to treat patients with COPD has increased over the past few decades. Most of the improvement has come from the modification of older compounds that are now more potent, of longer duration, and delivered in improved devices. They are now available as single, double, and even triple combinations that, although attempting to simplify administration, have also resulted in a large number of preparations. These medications are clearly effective and should be used as a central component of the multidimensional approach to the patient affected with COPD. The preferred route remains the inhaled direct delivery to the airways, but the favorable results obtained with systemic agents such as macrolides and roflumilast and the preliminary results of some biologicals are opening the door for the development of new drugs or reformulation of medications that have been used for other indications. Perhaps the most pressing need is to study the effect of these agents at early points in the course of the disease, because until now most, if not all, studies have been conducted in patients usually older than age 60 years, when most of the natural course of the disease has already been run. This monograph reviews the available pharmacological therapy based on current evidence and provides practical recommendations to health providers caring for patients with COPD.
引用
- Celli BR. Pharmacological Therapy of COPD: Reasons for Optimism. Chest. 2018. PMID: 30028967. doi:10.1016/j.chest.2018.07.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。